• Pasithea Therapeutics flagged initial Part A clinical data from its ongoing Phase 1/1b trial of PAS-004 in adults with neurofibromatosis type 1 for presentation at the European Neurofibromatosis Conference in Vienna on Nov. 12-14, 2026.
• The results have not yet been publicly disclosed.
• The company plans to present cutaneous neurofibromas data in an oral session on Nov. 13, 2026.
• Plexiform neurofibromas data is slated for a poster session on Nov. 12.
• Pasithea plans a follow-up release with detailed findings at the time of presentation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140700PRIMZONEFULLFEED9825919) on September 14, 2026, and is solely responsible for the information contained therein.